Tag: NCT04887259 clinical trial

LAVA Therapeutics gets FDA orphan drug status for LAVA-051 in CLL

LAVA Therapeutics has been granted orphan drug designation (ODD) in chronic lymphocytic leukemia (CLL) from the US Food and Drug Administration (FDA) for LAVA-051, its ... Read More